COMP <GO>
CRL vs MEDP // FORWARD P/E MULTIPLE
Charles River Laboratories International Inc. (NYSE) VS. Medpace Holdings Inc. (NASDAQ) • 15-METRIC TALLY: CRL 3
— MEDP 9
▲ FORWARD P/E MULTIPLE LEADER: CRL
LAST: $359.41 (-4.44%) • MKT CAP: $17.16B
forward-pe
23.0x
LAST: $652.01 (-3.77%) • MKT CAP: $18.24B
forward-pe
35.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRL VS. MEDP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRL | MEDP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.40% | 27.90% | -27.50 | MEDP | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 34.0x | +61.00 | MEDP | /valuation <GO> |
| Free Cash Flow Yield | 3.10% | 3.60% | -0.50 | MEDP | /fcf-yield <GO> |
| Operating Margin | 0.60% | 21.10% | -20.50 | MEDP | /operating-margins <GO> |
| Net Profit Margin | -3.60% | 17.80% | -21.40 | MEDP | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 20.00% | -20.90 | MEDP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.65 | 9.13 | -5.48 | MEDP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MEDP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.3 | 52.4 | +9.90 | CRL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.00 | +0.15 | CRL | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 23.0x | 35.3x | -12.30 | CRL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.16B | $18.24B | -$1.08B | MEDP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRL REV | MEDP REV | CRL GROSS % | MEDP GROSS % | CRL FCF | MEDP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.02B | $2.53B | — | — | $557.0M | $681.9M |
| FY 2024 | $4.05B | $2.11B | — | — | $552.3M | $572.3M |
| FY 2023 | $4.13B | $1.89B | — | — | $498.1M | $348.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRL // BETA 1.15
MEDP // BETA 1.00